Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Go, Ronald S  [Clear All Filters]
2016
Muchtar E, Dispenzieri A, Kumar SK, Dingli D, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Leung N, Chakraborty R, et al. Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. Haematologica. 2016.
Hwa YL, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Kourelis TV, Gonsalves WI, S Rajkumar V, Go RS, Leung N, et al. Induction Therapy Pre-Autologous Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis: A Retrospective Evaluation. Am J Hematol. 2016.
2019
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, et al. Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. Leukemia. 2019.
2021
Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, et al. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv. 2021;5(13):2753-2759.
2022
Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, et al. Deepening Responses Post Upfront ASCT in Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplant Cell Ther. 2022.
Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, S Rajkumar V, Dingli D, Go RS, Hayman SR, Kumar SK, et al. Multicentric Castleman disease - a single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022.
Mangaonkar AA, Langer KJ, Lasho TL, Finke C, Litzow MR, Hogan WJ, Shah MV, Go RS, Bartoo G, Kutzke J, et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients. Am J Hematol. 2022.